Key result
Review outlines potential effects of ACEi and ARBs on COVID-19 risk and cardiovascular outcomes.
Why the study?
The relationship between COVID-19, renin-angiotensin-aldosterone system function, and the impact of age and comorbidities on prognosis required clarification, including effects of ACE inhibitors and angiotensin receptor blockers.
This review discusses the theoretical and clinical implications of RAAS modulation (ACE inhibitors and ARBs) on the risk and severity of COVID-19, alongside the virus's cardiovascular effects.
Answers are grounded in this paper and cite their sources.
RAAS inhibitor use in COVID-19 remains uncertain; leaves open need for prospective trials on cardiovascular outcomes.
The review addressed the relationship of coronavirus disease 2019 (COVID-19) with functioning of the renin-angiotensin-aldosterone axis and the causes for unfavorable prognosis depending on patients' age and comorbidities. The authors discussed in detail potential effects of angiotensin-converting enzyme inhibitors and angiotensin II type 1 receptor antagonists on the risk of infection and the course of COVID-2019 as well as the effect of SARS-COV2 virus on the cardiovascular system.
No takes yet. Share an insight, caveat, or question.
Mareev et al. (2020) conducted a review in COVID-19. ACE inhibitors and angiotensin receptor blockers was evaluated. This review discusses the potential effects of ACE inhibitors and angiotensin receptor blockers on the risk and course of COVID-19, alongside the virus's impact on the cardiovascular system.
Synapse has enriched 10 related papers. Consider them for comparative context: